Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) by 17.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 338,945 shares of the company’s stock after purchasing an additional 49,999 shares during the quarter. […]
Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode.
/PRNewswire/ Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today.
Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the four brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average […]